Page 5 of 6
ACS Medicinal Chemistry Letters
16. Ross, R. A. L-alpha-lysophosphatidylinositol meets GPR55: a
deadly relationship. Trends Pharmacol. Sci. 2011, 32, 265-
269.
Corresponding Author
*Address correspondence
Pharmazeutisches Institut, An der Immenburg 4, D-53121 Bonn,
Germany, Phone: +49-228-73-2301, Fax: +49-228-73-2567, E-
mail: christa.mueller@uni-bonn.de
1
2
3
4
5
6
7
8
to:
Dr.
Christa
Müller,
17. Hattori, M.; Sakamoto, T.; Endo, Y.; Kakiuchi, N.; Kobashi,
K.; Mizuno, T.; Namba, T. Metabolism of magnolol from
magnoliae cortex. I. Application of liquid chromatography-
mass spectrometry to the analysis of metabolites of magnolol
in rats. Chem. Pharm. Bull. (Tokyo) 1984, 32, 5010-5017.
18. Hattori, M.; Endo, Y.; Takebe, S.; Kobashi, K.; Fukasaku, N.;
Namba, T. Metabolism of magnolol from Magnoliae cortex. II.
Absorption, metabolism and excretion of [ring-14C]magnolol
in rats. Chem. Pharm. Bull. (Tokyo) 1986, 34, 158-67.
19. Kong, Z. L.; Tzeng, S. C.; Liu, Y. C. Cytotoxic neolignans: an
SAR study. Bioorg. Med. Chem. Lett. 2005, 15, 163-166.
20. Ulrich, O.; Pfeiffer, H. P.; Breitmaier, E. Taschenporphyrine
mit intramolekularen Liganden. Chem. Ber. 1986, 119, 3507-
3514.
21. Konakahara, T.; Kiran, Y. B.; Okuno, Y.; Ikeda, R.; Sakai, N.
An expedient synthesis of ellipticine via Suzuki-Miyaura
coupling. Tetrahedron Lett. 2010, 51, 2335-2338.
22. Suzuki, A.; Miyaura, N. A. New stereospecific cross-coupling
by the palladium catalized reaction of 1-alkenylboranes with 1-
alkenyl or 1-alkynyl halides. Tetrahedron Lett. 1979, 36, 3437-
3440.
ACKNOWLEDGMENT
The authors thank Mrs. Walburga Hanekamp for technical
assistance.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
REFERENCES
1. Koetter, U.; Barrett, M.; Lacher, S.; Abdelrahman, A.;
Dolnick, D. Interactions of Magnolia and Ziziphus extracts
with selected central nervous system receptors. J.
Ethnopharmacol. 2009, 124, 421-425.
2. Lee, Y. J.; Lee, Y. M.; Lee, C. K.; Jung, J. K.; Han, S. B.;
Hong, J. T. Therapeutic applications of compounds in the
Magnolia family. Pharmacol. Ther. 2011, 130, 157-176.
3. Jada, S.; Reddy Doma, M.; Singh, P. P.; Kumar, S.; Malik, F.;
Sharma, A.; Khan, I. A.; Qazi, G. N.; Kumar, H. M. Design
and synthesis of novel magnolol derivatives as potential
antimicrobial and antiproliferative compounds. Eur. J. Med.
Chem. 2012, 51, 35-41.
4. Steinmann, P.; Walters, D. K.; Arlt, M. J.; Banke, I. J.; Ziegler,
U.; Langsam, B.; Arbiser, J.; Muff, R.; Born, W.; Fuchs, B.
Antimetastatic activity of honokiol in osteosarcoma. Cancer
2012, 118, 2117-2127.
5. Schuehly, W.; Khan, S. I.; Fischer, N. H. Neolignans from
North American Magnolia species with cyclooxygenase 2
inhibitory activity. Inflammopharmacology 2009, 17, 106-110.
6. Schuehly, W.; Paredes, J. M.; Kleyer, J.; Huefner, A.; Anavi-
Goffer, S.; Raduner, S.; Altmann, K. H.; Gertsch, J.
Mechanisms of osteoclastogenesis inhibition by a novel class
of biphenyl-type cannabinoid CB2 receptor inverse agonists.
Chem. Biol. 2011, 18, 1053-1064.
7. Zhang, H.; Xu, X.; Chen, L.; Chen, J.; Hu, L.; Jiang, H.; Shen,
X. Molecular determinants of magnolol targeting both
RXRalpha and PPARgamma. PLoS One 2011, 6, e28253.
8. Taferner, B.; Schuehly, W.; Huefner, A.; Baburin, I.; Wiesner,
K.; Ecker, G. F.; Hering, S. Modulation of GABAA-receptors
by honokiol and derivatives: subtype selectivity and structure-
activity relationship. J. Med. Chem. 2011, 54, 5349-5361.
9. Pacher, P.; Batkai, S.; Kunos, G. The endocannabinoid system
as an emerging target of pharmacotherapy. Pharmacol. Rev.
2006, 58, 389-462.
10. Toyota, M.; Kinugawa, T.; Asakawa, Y. Bibenzyl cannabinoid
and bisbibenzyl derivative from the liverwort Radula
perrottetii. Phytochemistry 1994, 37, 859-862.
11. Worm, K.; Zhou, Q. J.; Stabley, G. J.; DeHaven, R. N.; Dolle,
R. E. Biaryl cannabinoid mimetics-synthesis and structure-
activity relationship. Bioorg. Med. Chem. Lett. 2007, 17, 3652-
3656.
23. Agharahimi, M. R.; LeBel, N. A. Synthesis of (-)-
monoterpenylmagnolol and magnolol. J. Org. Chem. 1995, 60,
1856-1863.
24. Crosignani, S.; Pretre, A.; Jorand-Lebrun, C.; Fraboulet, G.;
Seenisamy, J.; Augustine, J. K.; Missotten, M.; Humbert, Y.;
Cleva, C.; Abla, N.; Daff, H.; Schott, O.; Schneider, M.;
Burgat-Charvillon, F.; Rivron, D.; Hamernig, I.; Arrighi, J. F.;
Gaudet, M.; Zimmerli, S. C.; Juillard, P.; Johnson, Z.
Discovery of potent, selective, and orally bioavailable
alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists
for the treatment of allergic inflammatory diseases. J. Med.
Chem. 2011, 54, 7299-7317.
25. Büchi, G.; Weinreb, S. M. Total syntheses of aflatoxins M1
and G1 and an improved synthesis of aflatoxin B1. J. Am.
Chem. Soc. 1940, 62, 1963-1967.
26. Van Rheenen, V.; Kelly, R. C.; Cha, D. Y. An improved
catalytic OsO4 oxidation of olefins to cis-1,2-glycols using
tertiary amine oxides as the oxidant. Tetrahedron Lett. 1976,
25, 1973-1976.
27. Behrenswerth, A.; Volz, N.; Torang, J.; Hinz, S.; Brase, S.;
Müller, C. E. Synthesis and pharmacological evaluation of
coumarin derivatives as cannabinoid receptor antagonists and
inverse agonists. Bioorg. Med. Chem. 2009, 17, 2842-2851.
28. Elsebai, M. F.; Rempel, V.; Schnakenburg, G.; Kehraus, S.;
Müller, C. E.; König, G. M. Identification of a potent and
selective cannabinoid CB1 receptor antagonist from
Auxarthron reticulatum. ACS Med. Chem. Lett. 2011, 2, 866-
869.
29. Forster, L.; Schulze Elfringhoff, A.; Lehr, M. High-
performance liquid chromatographic assay with fluorescence
detection for the evaluation of inhibitors against fatty acid
amide hydrolase. Anal. Bioanal. Chem. 2009, 394, 1679-1685.
30. Holtfrerich, A.; Makharadze, T.; Lehr, M. High-performance
liquid chromatography assay with fluorescence detection for
the evaluation of inhibitors against human recombinant
monoacylglycerol lipase. Anal. Biochem. 2010, 399, 218-224.
31. Pertwee, R. G. The therapeutic potential of drugs that target
cannabinoid receptors or modulate the tissue levels or actions
of endocannabinoids. Aaps J. 2005, 7, E625-654.
12. Kapur, A.; Zhao, P.; Sharir, H.; Bai, Y.; Caron, M. G.; Barak,
L. S.; Abood, M. E. Atypical responsiveness of the orphan
receptor GPR55 to cannabinoid ligands. J. Biol. Chem. 2009,
284, 29817-29827.
13. Geiger, S.; Nickl, K.; Schneider, E. H.; Seifert, R.; Heilmann,
J. Establishment of recombinant cannabinoid receptor assays
and characterization of several natural and synthetic ligands.
Naunyn Schmiedebergs Arch. Pharmacol. 2010, 382, 177-191.
14. Sharir, H.; Abood, M. E. Pharmacological characterization of
GPR55, a putative cannabinoid receptor. Pharmacol. Ther.
2010, 126, 301-313.
15. Henstridge, C. M.; Balenga, N. A.; Schröder, R.; Kargl, J. K.;
Platzer, W.; Martini, L.; Arthur, S.; Penman, J.; Whistler, J. L.;
Kostenis, E.; Waldhoer, M.; Irving, A. J. GPR55 ligands
promote receptor coupling to multiple signalling pathways. Br.
J. Pharmacol. 2010, 160, 604-614.
32. De Vry, J.; Denzer, D.; Reissmueller, E.; Eijckenboom, M.;
Heil, M.; Meier, H.; Mauler, F. 3-[2-cyano-3-(trifluoromethyl)
phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-
3074): a novel cannabinoid CB1/CB2 receptor partial agonist
with antihyperalgesic and antiallodynic effects. J. Pharmacol.
Exp. Ther. 2004, 310, 620-632.
5
ACS Paragon Plus Environment